{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T16:57:48Z","timestamp":1763398668463},"reference-count":78,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.berh.2005.05.003","type":"journal-article","created":{"date-parts":[[2005,9,8]],"date-time":"2005-09-08T13:07:56Z","timestamp":1126184876000},"page":"767-784","source":"Crossref","is-referenced-by-count":24,"title":["Management of \u2018refractory\u2019 skin disease in patients with lupus erythematosus"],"prefix":"10.1016","volume":"19","author":[{"given":"Jeffrey P.","family":"Callen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2005.05.003_bib1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/berh.2001.0224","article-title":"Management of skin disease in patients with lupus erythematosus","volume":"16","author":"Callen","year":"2002","journal-title":"Best Practice and Research: Clinical Rheumatology"},{"key":"10.1016\/j.berh.2005.05.003_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archderm.139.1.45","article-title":"Drug-induced, Ro\/SSA-positive cutaneous lupus erythematosus","volume":"139","author":"Srivastava","year":"2003","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archderm.139.1.89","article-title":"How frequently are drugs associated with the development or exacerbation of subacute cutaneous lupus?","volume":"139","author":"Callen","year":"2003","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-4632.2004.02013.x","article-title":"Lupus erythematosus induced by medications, ultraviolet radiation, and other exogenous agents: a review, with special focus on the development of subacute cutaneous lupus erythematosus in a genetically predisposed individual","volume":"43","author":"Shapiro","year":"2004","journal-title":"International Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1600-0781.2004.00094.x","article-title":"Photosensitivity in lupus erythematosus","volume":"20","author":"Scheinfeld","year":"2004","journal-title":"Photodermatology, Photoimmunology and Photomedicine"},{"key":"10.1016\/j.berh.2005.05.003_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0190-9622(90)70020-I","article-title":"Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation","volume":"22","author":"Lehmann","year":"1990","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"11","key":"10.1016\/j.berh.2005.05.003_bib7","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2005.05.003_bib8","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archderm.127.7.1006","article-title":"Twenty percent of biopsy specimens from sun-exposed skin of normal young adults demonstrate positive immunofluorescence","volume":"127","author":"Fabre","year":"1991","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.1529-8019.2001.014002061.x","article-title":"Therapy of cutaneous lupus erythematosus","volume":"14","author":"Callen","year":"2001","journal-title":"Dermatologic Therapy"},{"key":"10.1016\/j.berh.2005.05.003_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-2133.2004.06196.x","article-title":"Update on the management of cutaneous lupus erythematosus","volume":"151","author":"Callen","year":"2004","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib11","first-page":"257","article-title":"Evidence-based evaluation of immunomodulatory therapy of cutaneous manifestations of lupus","volume":"20","author":"Heath","year":"2004","journal-title":"Advances in Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib12","first-page":"CD002954","article-title":"Drugs for discoid lupus erythematosus","volume":"1","author":"Jessop","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.berh.2005.05.003_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.7326\/0003-4819-103-1-49","article-title":"Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy","volume":"103","author":"Reed","year":"1985","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.berh.2005.05.003_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0046-8177(97)90281-1","article-title":"Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy","volume":"28","author":"Crowson","year":"1997","journal-title":"Human Pathology"},{"issue":"9","key":"10.1016\/j.berh.2005.05.003_bib15","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/archderm.137.9.1196","article-title":"Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases","volume":"137","author":"Callen","year":"2001","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib16","first-page":"231","article-title":"Report of an association between discoid lupus erythematosus and smoking","volume":"63","author":"Gallego","year":"1999","journal-title":"Cutis"},{"key":"10.1016\/j.berh.2005.05.003_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1034\/j.1600-0781.2000.160604.x","article-title":"Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test","volume":"16","author":"Stege","year":"2000","journal-title":"Photodermatology, Photoimmunology and Photomedicine"},{"key":"10.1016\/j.berh.2005.05.003_bib18","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1002\/art.20426","article-title":"Use of sunscreens to protect against ultraviolet-induced lupus erythematosus","volume":"50","author":"Herzinger","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2005.05.003_bib19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/keh325","article-title":"Topical tacrolimus therapy of resistant cutaneous lesion in lupus erythematosus: a possible alternative","volume":"43","author":"Lampropoulos","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2005.05.003_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000074119","article-title":"Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus","volume":"207","author":"B\u00f6hm","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2004.01.044","article-title":"Pimecrolimus 1% cream for cutaneous lupus erythematosus","volume":"51","author":"Kreuter","year":"2004","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000066428","article-title":"Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod","volume":"205","author":"Gerdsen","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib23","article-title":"Systemic lupus erythematosus arising during interferon-alpha therapy for cyroglobulinemic vasculitis associated with hepatitis C","author":"Neiwold","year":"2004","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.berh.2005.05.003_bib24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/09546630310019904","article-title":"Discoid lupus erythematosus treated with cryotherapy","volume":"14","author":"Molin","year":"2003","journal-title":"The Journal of Dermatological Treatment"},{"key":"10.1016\/j.berh.2005.05.003_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000018467","article-title":"Successful treatment of discoid lupus erythematosus with argon laser","volume":"201","author":"Kuhn","year":"2000","journal-title":"Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/lsm.10169","article-title":"Treatment of lupus erythematosus with pulsed dye laser","volume":"32","author":"Baniandr\u00e9s","year":"2003","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.berh.2005.05.003_bib27","first-page":"1716","article-title":"Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus","volume":"25","author":"Rahman","year":"1998","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.berh.2005.05.003_bib28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0190-9622(00)90290-1","article-title":"Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment","volume":"42","author":"Jewell","year":"2000","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1159\/000246899","article-title":"The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus","volume":"189","author":"Feldmann","year":"1994","journal-title":"Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000246710","article-title":"Chloroquine-quinacrine association in resistant cutaneous lupus","volume":"190","author":"Lipsker","year":"1995","journal-title":"Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1191\/096120300678828082","article-title":"The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients","volume":"9","author":"Toubi","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2005.05.003_bib32","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/eye.1998.236","article-title":"Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine","volume":"12","author":"Fielder","year":"1998","journal-title":"Eye"},{"key":"10.1016\/j.berh.2005.05.003_bib33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archderm.118.6.412","article-title":"Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic and prognostic examination of 62 patients","volume":"118","author":"Callen","year":"1982","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.1982.tb00910.x","article-title":"Dapsone and discoid lupus erythematosus","volume":"106","author":"Coburn","year":"1982","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib35","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000249338","article-title":"Dapsone in the treatment of cutaneous lupus erythematosus","volume":"172","author":"Lindskov","year":"1986","journal-title":"Dermatologica"},{"key":"10.1016\/j.berh.2005.05.003_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2133.1981.tb01711.x","article-title":"Dapsone in the treatment of lupus erythematosus","volume":"104","author":"Ruzicka","year":"1981","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2230.1986.tb00433.x","article-title":"Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus","volume":"11","author":"Fenton","year":"1986","journal-title":"Clinical and Experimental Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-97-2-165","article-title":"Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy","volume":"97","author":"Hall","year":"1982","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.berh.2005.05.003_bib39","first-page":"122","article-title":"Dapsone is an effective therapy for the skin lesions of Subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency","volume":"17","author":"Holtman","year":"1990","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.berh.2005.05.003_bib40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1191\/096120399678847713","article-title":"A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with dapsone","volume":"8","author":"Neri","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2005.05.003_bib41","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1440-0960.1976.tb00801.x","article-title":"Clofazimine (lamprene) in the treatment of discoid lupus erythematosus","volume":"17","author":"Krivanek","year":"1976","journal-title":"The Australasian Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1440-0960.1980.tb00162.x","article-title":"Further study of the use of clofazimine in discoid lupus erythematosus","volume":"21","author":"Krivanek","year":"1980","journal-title":"The Australasian Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000018345","article-title":"Long-term cefuroxime axetil in subacute cutaneous lupus erythematosus. A report of three cases","volume":"200","author":"Rudnicka","year":"2000","journal-title":"Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib44","first-page":"151","article-title":"Traitment du lupus erythemateux chronique par la sulfasalazine: 11 observations","volume":"124","author":"Delaporte","year":"1997","journal-title":"Annales de Dermatologie et de Venereologie"},{"key":"10.1016\/j.berh.2005.05.003_bib45","first-page":"21","article-title":"Sulfasalazine in the treatment of cutaneous lupus erythematosus: open trial in six cases","volume":"7","author":"Lagrange","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2005.05.003_bib46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2133.1986.tb05720.x","article-title":"Treatment of chronic discoid lupus erythematosus with an oral gold compound (Auranofin)","volume":"115","author":"Dalziel","year":"1986","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/09546639109089051","article-title":"Auranofin in the treatment of discoid lupus erythematosus","volume":"2","author":"Stenjker","year":"1991","journal-title":"The Journal of Dermatological Treatment"},{"key":"10.1016\/j.berh.2005.05.003_bib48","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1600-0781.2003.00055.x","article-title":"Thalidomide inhibits UVB-induced mouse keratinocytes apoptosis by both TNF-a-dependent and TNF-a-independent pathways","volume":"19","author":"Lu","year":"2003","journal-title":"Photodermatology, Photoimmunology and Photomedicine"},{"key":"10.1016\/j.berh.2005.05.003_bib49","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2133.2004.06117.x","article-title":"Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: discordant effects on minimal erythema dose and sunburn cell formation","volume":"151","author":"Cummins","year":"2004","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib50","first-page":"487","article-title":"Treatment of cutaneous lesions of systemic lupus erythematosus with thalidomide","volume":"11","author":"Atra","year":"1993","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.berh.2005.05.003_bib51","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archderm.135.9.1079","article-title":"American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus","volume":"135","author":"Duong","year":"1999","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archderm.139.1.50","article-title":"Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus","volume":"139","author":"Housman","year":"2003","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib53","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1747.2002.19502.x","article-title":"Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients","volume":"119","author":"Bastuji-Garin","year":"2002","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib54","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00128071-200304060-00002","article-title":"Thalidomide in cutaneous lupus erythematosus","volume":"4","author":"Pelle","year":"2003","journal-title":"American Journal of Clinical Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib55","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/archderm.131.5.620b","article-title":"Phenytoin in the treatment of discoid lupus erythematosus","volume":"131","author":"Rodriquez-Castellanos","year":"1995","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib56","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/archderm.122.2.170","article-title":"Mechanism-oriented assessment of isotretinoin in chronic of subacute cutaneous lupus erythematosus","volume":"122","author":"Newton","year":"1986","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib57","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-4362.1990.tb03476.x","article-title":"Subacute cutaneous lupus erythematosus response to isotretinoin","volume":"29","author":"Furner","year":"1990","journal-title":"International Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib58","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2340\/0001555565324329","article-title":"Treatment of cutaneous lupus erythematosus with etretinate","volume":"65","author":"Ruzicka","year":"1985","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1016\/j.berh.2005.05.003_bib59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/09546638909086682","article-title":"Coexistent psoriasis and lupus erythematosus: successful therapy with etretinate","volume":"1","author":"Green","year":"1989","journal-title":"The Journal of Dermatological Treatment"},{"key":"10.1016\/j.berh.2005.05.003_bib60","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/archderm.127.4.515","article-title":"Azathioprine: an effective, corticosteroids-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis","volume":"127","author":"Callen","year":"1991","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib61","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/archderm.121.10.1323","article-title":"Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus","volume":"121","author":"Tsokos","year":"1985","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib62","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0190-9622(88)70259-5","article-title":"Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine","volume":"19","author":"Ashinoff","year":"1988","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib63","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archderm.130.7.938","article-title":"Discoid lupus erythematosus: successful treatment with oral methotrexate","volume":"130","author":"Goldstein","year":"1994","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2133.1995.tb02637.x","article-title":"Methotrexate for the treatment of severe mucocutaneous lupus erythematosus","volume":"133","author":"Bottomley","year":"1995","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s002960050058","article-title":"Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms","volume":"18","author":"Boehm","year":"1998","journal-title":"Rheumatology International"},{"key":"10.1016\/j.berh.2005.05.003_bib66","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1001\/archderm.138.12.1616","article-title":"Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement","volume":"138","author":"Hanjani","year":"2002","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib67","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1365-2133.2002.04875.x","article-title":"Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil","volume":"147","author":"Schanz","year":"2002","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib68","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/art.1780380926","article-title":"Cytarabine therapy for refractory cutaneous lupus erythematosus","volume":"38","author":"Yung","year":"1995","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2005.05.003_bib69","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2133.1971.tb14112.x","article-title":"Treatment of discoid and subacute cutaneous lupus erythematosus with cyclophosphamide","volume":"85","author":"Schulz","year":"1971","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib70","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archderm.122.9.973a","article-title":"Cyclosporine in the treatment of lupus erythematosus","volume":"122","author":"Heule","year":"1986","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib71","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2133.1994.tb08471.x","article-title":"Cyclosporin and discoid lupus erythematosus","volume":"131","author":"Yell","year":"1994","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib72","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2340\/00015555768788","article-title":"Discoid lupus erythematosus during treatment with cyclosporine","volume":"76","author":"Lernia","year":"1996","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1016\/j.berh.2005.05.003_bib73","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/09546630310018789","article-title":"Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE)","volume":"15","author":"Goodfield","year":"2004","journal-title":"The Journal of Dermatological Treatment"},{"key":"10.1016\/j.berh.2005.05.003_bib74","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/archderm.135.9.1124","article-title":"High-dose intravenous immunoglobulin in cutaneous lupus erythematosus","volume":"135","author":"Genereau","year":"1999","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib75","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.10271","article-title":"Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent","volume":"46","author":"Fautrel","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2005.05.003_bib76","doi-asserted-by":"crossref","first-page":"142S","DOI":"10.1111\/1523-1747.ep12875049","article-title":"Response of discoid and subacute cutaneous lupus erythematosus to recombinant interferon alpha 2a","volume":"95","author":"Nicolas","year":"1990","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib77","first-page":"253","article-title":"Therapy of cutaneous lupus erythematosus with recombinant interferon alpha-2a","volume":"2","author":"Tebbe","year":"1992","journal-title":"European Journal of Dermatology"},{"key":"10.1016\/j.berh.2005.05.003_bib78","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0190-9622(96)80119-8","article-title":"Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412","volume":"34","author":"Prinz","year":"1996","journal-title":"Journal of the American Academy of Dermatology"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694205000501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694205000501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T14:26:27Z","timestamp":1706538387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694205000501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S1521694205000501"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2005.05.003","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}